OVERCOME CANCER RESISTANCE
NETRIS Pharma develops first-in-class therapeutics to overcome resistance in oncology by targeting Netrin-1
Best-in-Class Environment to foster Therapeutic Innovation
NETRIS Pharma is the first spin-off of Centre Léon Bérard and the Cancer Research Center of Lyon – CRCL – (Lyon, France) and benefits from the exceptional environment of this world’s renowned comprehensive center dedicated to cancer care, education and research.
Our news
10/23/2025
Patrick Mehlen to present the Ohdang Award Lecture at the 2025 Fall International Convention of the Pharmaceutical Society of Korea
10/19/2025
NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at the ESMO Congress 2025
10/19/2025
NETRIS Pharma to present the IMMUNONET abstract at the 2025 ESMO in Berlin
Our publications
06/04/2025
Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival
10/18/2024
Netrin-1 feedforward mechanism promotes pancreatic cancer liver metastasis via hepatic stellate cell activation, retinoid, and ELF3 signaling
08/30/2023
Blockade of netrin-1 is a promising strategy against endometrial cancer - Clinical briefing
Strategic Focus on Intellectual Property Rights
As the world pioneer and leader biopharmaceutical company targeting netrin-1 and ligands of Dependence Receptors, NETRIS Pharma is building a unique portfolio of worldwide exclusive rights and patents on all key elements of its approach.
Our partners
NETRIS Pharma has grown from inception with the full support of Research, Clinical and Corporate Partners.
Clinical
Corporate
Research
